PEDIATRIX MEDICAL GROUP INC (MD) Fundamental Analysis & Valuation

NYSE:MD • US58502B1061

Current stock price

21.81 USD
+0.36 (+1.68%)
At close:
21.81 USD
0 (0%)
After Hours:

This MD fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

7

1. MD Profitability Analysis

1.1 Basic Checks

  • MD had positive earnings in the past year.
  • MD had a positive operating cash flow in the past year.
  • The reported net income has been mixed in the past 5 years: MD reported negative net income in multiple years.
  • In the past 5 years MD always reported a positive cash flow from operatings.
MD Yearly Net Income VS EBIT VS OCF VS FCFMD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500M -500M -1B

1.2 Ratios

  • The Return On Assets of MD (7.36%) is better than 88.00% of its industry peers.
  • MD has a Return On Equity of 19.10%. This is amongst the best in the industry. MD outperforms 86.00% of its industry peers.
  • MD has a Return On Invested Capital of 9.88%. This is amongst the best in the industry. MD outperforms 82.00% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for MD is in line with the industry average of 8.51%.
  • The 3 year average ROIC (8.21%) for MD is below the current ROIC(9.88%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 7.36%
ROE 19.1%
ROIC 9.88%
ROA(3y)0.01%
ROA(5y)1.53%
ROE(3y)-0.32%
ROE(5y)4.22%
ROIC(3y)8.21%
ROIC(5y)7.97%
MD Yearly ROA, ROE, ROICMD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -20 -40 -60 -80 -100

1.3 Margins

  • MD has a Profit Margin of 8.64%. This is amongst the best in the industry. MD outperforms 92.00% of its industry peers.
  • MD's Profit Margin has improved in the last couple of years.
  • With an excellent Operating Margin value of 12.07%, MD belongs to the best of the industry, outperforming 85.00% of the companies in the same industry.
  • In the last couple of years the Operating Margin of MD has grown nicely.
Industry RankSector Rank
OM 12.07%
PM (TTM) 8.64%
GM N/A
OM growth 3Y5.99%
OM growth 5Y4.02%
PM growth 3Y36.96%
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MD Yearly Profit, Operating, Gross MarginsMD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -20 -40 -60 -80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. MD Health Analysis

2.1 Basic Checks

  • MD has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
  • MD has less shares outstanding than it did 1 year ago.
  • The number of shares outstanding for MD has been reduced compared to 5 years ago.
  • The debt/assets ratio for MD has been reduced compared to a year ago.
MD Yearly Shares OutstandingMD Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M
MD Yearly Total Debt VS Total AssetsMD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B 4B 5B

2.2 Solvency

  • An Altman-Z score of 2.08 indicates that MD is not a great score, but indicates only limited risk for bankruptcy at the moment.
  • With a Altman-Z score value of 2.08, MD perfoms like the industry average, outperforming 53.00% of the companies in the same industry.
  • MD has a debt to FCF ratio of 2.36. This is a good value and a sign of high solvency as MD would need 2.36 years to pay back of all of its debts.
  • The Debt to FCF ratio of MD (2.36) is better than 72.00% of its industry peers.
  • MD has a Debt/Equity ratio of 0.66. This is a neutral value indicating MD is somewhat dependend on debt financing.
  • MD has a Debt to Equity ratio (0.66) which is in line with its industry peers.
  • Even though the debt/equity ratio score it not favorable for MD, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
Industry RankSector Rank
Debt/Equity 0.66
Debt/FCF 2.36
Altman-Z 2.08
ROIC/WACC1.17
WACC8.47%
MD Yearly LT Debt VS Equity VS FCFMD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B

2.3 Liquidity

  • MD has a Current Ratio of 1.66. This is a normal value and indicates that MD is financially healthy and should not expect problems in meeting its short term obligations.
  • The Current ratio of MD (1.66) is better than 67.00% of its industry peers.
  • A Quick Ratio of 1.66 indicates that MD should not have too much problems paying its short term obligations.
  • With a decent Quick ratio value of 1.66, MD is doing good in the industry, outperforming 68.00% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.66
Quick Ratio 1.66
MD Yearly Current Assets VS Current LiabilitesMD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. MD Growth Analysis

3.1 Past

  • MD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 36.24%, which is quite impressive.
  • Measured over the past years, MD shows a quite strong growth in Earnings Per Share. The EPS has been growing by 10.01% on average per year.
  • The Revenue has decreased by -4.92% in the past year.
  • MD shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 1.99% yearly.
EPS 1Y (TTM)36.24%
EPS 3Y6.72%
EPS 5Y10.01%
EPS Q2Q%-1.96%
Revenue 1Y (TTM)-4.92%
Revenue growth 3Y-0.99%
Revenue growth 5Y1.99%
Sales Q2Q%-1.71%

3.2 Future

  • Based on estimates for the next years, MD will show a small growth in Earnings Per Share. The EPS will grow by 0.99% on average per year.
  • The Revenue is expected to grow by 3.93% on average over the next years.
EPS Next Y13.36%
EPS Next 2Y8.67%
EPS Next 3Y4.87%
EPS Next 5Y0.99%
Revenue Next Year1.07%
Revenue Next 2Y1.84%
Revenue Next 3Y2.77%
Revenue Next 5Y3.93%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
MD Yearly Revenue VS EstimatesMD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 1B 2B 3B
MD Yearly EPS VS EstimatesMD Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 1 2 3 4

More info and screens

Find the best growth stocksShow best growing peers

8

4. MD Valuation Analysis

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 10.74, the valuation of MD can be described as reasonable.
  • Based on the Price/Earnings ratio, MD is valued cheaper than 91.00% of the companies in the same industry.
  • When comparing the Price/Earnings ratio of MD to the average of the S&P500 Index (27.18), we can say MD is valued rather cheaply.
  • Based on the Price/Forward Earnings ratio of 9.48, the valuation of MD can be described as reasonable.
  • Based on the Price/Forward Earnings ratio, MD is valued cheaper than 92.00% of the companies in the same industry.
  • MD is valuated cheaply when we compare the Price/Forward Earnings ratio to 37.96, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 10.74
Fwd PE 9.48
MD Price Earnings VS Forward Price EarningsMD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, MD is valued cheaply inside the industry as 88.00% of the companies are valued more expensively.
  • 89.00% of the companies in the same industry are more expensive than MD, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 7.17
EV/EBITDA 6.94
MD Per share dataMD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15 20

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • The decent profitability rating of MD may justify a higher PE ratio.
PEG (NY)0.8
PEG (5Y)1.07
EPS Next 2Y8.67%
EPS Next 3Y4.87%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. MD Dividend Analysis

5.1 Amount

  • MD does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

MD Fundamentals: All Metrics, Ratios and Statistics

PEDIATRIX MEDICAL GROUP INC

NYSE:MD (4/13/2026, 5:05:00 PM)

After market: 21.81 0 (0%)

21.81

+0.36 (+1.68%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)02-19
Earnings (Next)04-30
Inst Owners103.94%
Inst Owner Change0%
Ins Owners2.05%
Ins Owner Change-0.8%
Market Cap1.81B
Revenue(TTM)1.91B
Net Income(TTM)165.39M
Analysts78.67
Price Target21.76 (-0.23%)
Short Float %3.74%
Short Ratio3.47
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)14.87%
Min EPS beat(2)-9.94%
Max EPS beat(2)39.68%
EPS beat(4)3
Avg EPS beat(4)20.9%
Min EPS beat(4)-9.94%
Max EPS beat(4)39.68%
EPS beat(8)7
Avg EPS beat(8)17.99%
EPS beat(12)7
Avg EPS beat(12)8.59%
EPS beat(16)8
Avg EPS beat(16)5.12%
Revenue beat(2)1
Avg Revenue beat(2)-0.49%
Min Revenue beat(2)-1.41%
Max Revenue beat(2)0.42%
Revenue beat(4)1
Avg Revenue beat(4)-1.1%
Min Revenue beat(4)-1.97%
Max Revenue beat(4)0.42%
Revenue beat(8)2
Avg Revenue beat(8)-1.43%
Revenue beat(12)2
Avg Revenue beat(12)-2.28%
Revenue beat(16)2
Avg Revenue beat(16)-2.52%
PT rev (1m)-0.78%
PT rev (3m)-5.88%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-1.3%
EPS NY rev (1m)0%
EPS NY rev (3m)2.14%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-1.72%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.59%
Valuation
Industry RankSector Rank
PE 10.74
Fwd PE 9.48
P/S 0.95
P/FCF 7.17
P/OCF 6.68
P/B 2.09
P/tB N/A
EV/EBITDA 6.94
EPS(TTM)2.03
EY9.31%
EPS(NY)2.3
Fwd EY10.55%
FCF(TTM)3.04
FCFY13.94%
OCF(TTM)3.26
OCFY14.96%
SpS23.04
BVpS10.42
TBVpS-4.96
PEG (NY)0.8
PEG (5Y)1.07
Graham Number21.82
Profitability
Industry RankSector Rank
ROA 7.36%
ROE 19.1%
ROCE 12.93%
ROIC 9.88%
ROICexc 13.71%
ROICexgc 1686.9%
OM 12.07%
PM (TTM) 8.64%
GM N/A
FCFM 13.2%
ROA(3y)0.01%
ROA(5y)1.53%
ROE(3y)-0.32%
ROE(5y)4.22%
ROIC(3y)8.21%
ROIC(5y)7.97%
ROICexc(3y)10.42%
ROICexc(5y)9.77%
ROICexgc(3y)618.91%
ROICexgc(5y)394.62%
ROCE(3y)10.75%
ROCE(5y)10.43%
ROICexgc growth 3Y208.98%
ROICexgc growth 5Y85.34%
ROICexc growth 3Y17.7%
ROICexc growth 5Y11.82%
OM growth 3Y5.99%
OM growth 5Y4.02%
PM growth 3Y36.96%
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score8
Asset Turnover0.85
Health
Industry RankSector Rank
Debt/Equity 0.66
Debt/FCF 2.36
Debt/EBITDA 2.26
Cap/Depr 84.57%
Cap/Sales 0.96%
Interest Coverage 6.72
Cash Conversion 107.19%
Profit Quality 152.75%
Current Ratio 1.66
Quick Ratio 1.66
Altman-Z 2.08
F-Score8
WACC8.47%
ROIC/WACC1.17
Cap/Depr(3y)81.68%
Cap/Depr(5y)85.74%
Cap/Sales(3y)1.24%
Cap/Sales(5y)1.38%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)36.24%
EPS 3Y6.72%
EPS 5Y10.01%
EPS Q2Q%-1.96%
EPS Next Y13.36%
EPS Next 2Y8.67%
EPS Next 3Y4.87%
EPS Next 5Y0.99%
Revenue 1Y (TTM)-4.92%
Revenue growth 3Y-0.99%
Revenue growth 5Y1.99%
Sales Q2Q%-1.71%
Revenue Next Year1.07%
Revenue Next 2Y1.84%
Revenue Next 3Y2.77%
Revenue Next 5Y3.93%
EBIT growth 1Y25.81%
EBIT growth 3Y4.93%
EBIT growth 5Y6.1%
EBIT Next Year16.33%
EBIT Next 3Y6.84%
EBIT Next 5YN/A
FCF growth 1Y36.89%
FCF growth 3Y22.56%
FCF growth 5Y7.52%
OCF growth 1Y31.23%
OCF growth 3Y17.54%
OCF growth 5Y5.79%

PEDIATRIX MEDICAL GROUP INC / MD Fundamental Analysis FAQ

What is the ChartMill fundamental rating of PEDIATRIX MEDICAL GROUP INC (MD) stock?

ChartMill assigns a fundamental rating of 6 / 10 to MD.


Can you provide the valuation status for PEDIATRIX MEDICAL GROUP INC?

ChartMill assigns a valuation rating of 8 / 10 to PEDIATRIX MEDICAL GROUP INC (MD). This can be considered as Undervalued.


Can you provide the profitability details for PEDIATRIX MEDICAL GROUP INC?

PEDIATRIX MEDICAL GROUP INC (MD) has a profitability rating of 7 / 10.


Can you provide the financial health for MD stock?

The financial health rating of PEDIATRIX MEDICAL GROUP INC (MD) is 6 / 10.